Key result
Voltage-gated potassium channels (Kv) are detailed in the IUPHAR/BPS Guide to Pharmacology database version 2023.1 as key pharmacological targets for treating human excitability disorders.
Key points are not available for this paper at this time.
Provides an expert-driven guide and database links for the pharmacological targets of voltage-gated potassium channels.
The 6TM family of K channels comprises the voltage-gated KV subfamilies, the EAG subfamily (which includes hERG channels), the Ca2+-activated Slo subfamily (actually with 7TM, termed BK) and the Ca2+-activated SK subfamily. These channels possess a pore-forming α subunit that comprise tetramers of identical subunits (homomeric) or of different subunits (heteromeric). Heteromeric channels can only be formed within subfamilies (e.g. Kv1.1 with Kv1.2; Kv7.2 with Kv7.3). The pharmacology largely reflects the subunit composition of the functional channel.Kv7 channelsKv7.1-Kv7.5 (KCNQ1-5) K+ channels are voltage-gated K+ channels with major roles in neurons, muscle cells and epithelia where they underlie physiologically important K+ currents, such as the neuronal M-current and the cardiac IKs. Genetic deficiencies in all five KCNQ genes result in human excitability disorders, including epilepsy, autism spectrum disorders, cardiac arrhythmias and deafness. Thanks to the recent knowledge of the structure and function of human KCNQ-encoded proteins, these channels are increasingly used as drug targets for treating diseases [326, 2, 767].
No takes yet. Share an insight, caveat, or question.
Attali et al. (2023) studied this question. Voltage-gated potassium channels (Kv) are detailed in the IUPHAR/BPS Guide to Pharmacology database version 2023.1 as key pharmacological targets for treating human excitability disorders.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: